Categories Earnings, Technology, U.S. Markets News

Qualcomm-NXP deal getting delayed, thanks to China-US spat

We had last month listed the companies that would be affected in the event of a trade war between the US and China. And Qualcomm Inc (QCOM) was one of them. As predicted, Qualcomm is now caught up in this mess between both the countries.

Qualcomm’s proposed acquisition of NXP Semiconductors (NXPI) is getting delayed as China is allegedly dilly-dallying with approvals. It may be noted that the deal has secured approvals from all other jurisdictions.

The underlying trade issues between the US and China are being cited as the primary reasons for the delay. Qualcomm withdrew its antitrust application on Saturday at the behest of the Ministry of Commerce and will refile it at the earliest giving the ministry another six months to review the deal.

The NXP deal is important to Qualcomm and there are concerns that China could use it as leverage to gain an edge in the current trade situation. Qualcomm is said to have assured the Ministry of Commerce of a waiver for NXP customers from purchasing Qualcomm’s licenses. The deadline for completion of the deal is April 25.

The Qualcomm deal is not the only one put on hold by the Chinese government. They have also halted the sale of Toshiba’s memory chip business to a Bain Capital-led consortium due to trade pressures.

Qualcomm, meanwhile, is also dealing with legal issues with Apple Inc. (AAPL) which could cost it a huge amount in fines. If the deal gets cancelled, Qualcomm will have to pay NXP a separation fee, which would hurt its operating cash flow.

Qualcomm believes the NXP merger will be beneficial to it in terms of opportunities in the Internet of Things market, which it estimates to be worth over $75 billion over the next two years.

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top